Piper Alderman Partner | NED | Life Sciences & Healthcare | Refreshingly practical advice for innovative organisations | Corporate Governance | M & A | Capital Raising | Collaborations | GAICD | FGIA
A panel discussion on #capitalmarkets at #ausmedtech2024 moderated by Bronwyn Le Grice with Steve Burnell Elyse Shapiro Chris Nave and Jo Chaturvedi- Durant : 📉 the heights of investment and valuations in 2021 and the fall-off in 2023 didn’t necessarily affect #medtech 📈with record numbers of FDA approvals of medical devices last year the sector is hopefully positioned for uplift 💭 funds have been holding on to capital and channeling it to their existing portfolio 🩺 medical devices may be a simpler investment proposition but investors can still experience shocks with problems in reimbursement for example 💰potential acquirers are waiting for companies to generate revenue rather than buying on good clinical results 🏹 we have the money here; we need to convince the super funds to unlock it➡️the more wins we have (which requires international capital at this point) the more evidence we have to persuade them 🤝 being partnered with big medtech is accretive in the eyes of investors 🚛 one challenge with the ASX is the lack of specialist analysts and specialised investors 💥 differing views on whether debt is attractive or a deterrent for investors 💰 be aware of non-dilutive funding opportunities here (eg MRFF) and overseas (eg BARDA) 🩺 lay the groundwork for bringing in specialist investors from US/EU by bringing in KOLs from there #venturecapital #asx #capitalraising
Founder & Executive Director at Peak Asset Management
1moA great event!